196 related articles for article (PubMed ID: 29374320)
1. Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents.
Ciolina M; Di Martino M; Bruno O; Pommier R; Vilgrain V; Ronot M
Eur Radiol; 2018 Jul; 28(7):3020-3031. PubMed ID: 29374320
[TBL] [Abstract][Full Text] [Related]
2. Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin.
Bonatti M; Valletta R; Zamboni GA; Lombardo F; Senoner M; Simioni M; Schifferle G; Bonatti G
Eur Radiol; 2019 Jun; 29(6):2830-2836. PubMed ID: 30643946
[TBL] [Abstract][Full Text] [Related]
3. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
[TBL] [Abstract][Full Text] [Related]
4. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
5. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.
Dahlqvist Leinhard O; Dahlström N; Kihlberg J; Sandström P; Brismar TB; Smedby O; Lundberg P
Eur Radiol; 2012 Mar; 22(3):642-53. PubMed ID: 21984449
[TBL] [Abstract][Full Text] [Related]
6. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors.
Lewis S; Vasudevan P; Chatterji M; Besa C; Jajamovich G; Facciuto M; Taouli B
Abdom Radiol (NY); 2016 Jul; 41(7):1300-9. PubMed ID: 26960727
[TBL] [Abstract][Full Text] [Related]
7. Liver enhancement during hepatobiliary phase after Gd-BOPTA administration: correlation with liver and renal function.
Bonatti M; Valletta R; Avesani G; Lombardo F; Cannone F; Zamboni GA; Mansueto G; Manfredi R; Ferro F
Eur Radiol; 2021 Apr; 31(4):2490-2496. PubMed ID: 33000303
[TBL] [Abstract][Full Text] [Related]
8. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA.
Runge VM
J Comput Assist Tomogr; 1998; 22(4):643-50. PubMed ID: 9676461
[TBL] [Abstract][Full Text] [Related]
9. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
Yeom SK; Byun JH; Kim HJ; Park SH; Kim N; Shin YM; Kim PN
Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
[TBL] [Abstract][Full Text] [Related]
10. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
11. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
12. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
[TBL] [Abstract][Full Text] [Related]
13. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
14. Lesion detection and assessment of extrahepatic findings in abdominal MRI using hepatocyte specific contrast agents--comparison of Gd-EOB-DTPA and Gd-BOPTA.
Ringe KI; Boll DT; Husarik DB; Bashir MR; Gupta RT; Merkle EM
BMC Med Imaging; 2013 Mar; 13():10. PubMed ID: 23506523
[TBL] [Abstract][Full Text] [Related]
15. [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].
Stroszczynski C; Gaffke G; Gnauck M; Streitparth F; Wieners G; Lopez-Häninnen E
Radiologe; 2004 Dec; 44(12):1185-91. PubMed ID: 15549226
[TBL] [Abstract][Full Text] [Related]
16. MR liver imaging with Gd-EOB-DTPA: a delay time of 10 minutes is sufficient for lesion characterisation.
van Kessel CS; Veldhuis WB; van den Bosch MA; van Leeuwen MS
Eur Radiol; 2012 Oct; 22(10):2153-60. PubMed ID: 22645040
[TBL] [Abstract][Full Text] [Related]
17. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
[TBL] [Abstract][Full Text] [Related]
18. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla.
Verloh N; Haimerl M; Zeman F; Schlabeck M; Barreiros A; Loss M; Schreyer AG; Stroszczynski C; Fellner C; Wiggermann P
Eur Radiol; 2014 May; 24(5):1013-9. PubMed ID: 24531844
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
Feuerlein S; Gupta RT; Boll DT; Merkle EM
Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
[TBL] [Abstract][Full Text] [Related]
20. Intrahepatic mass-forming cholangiocarcinoma: enhancement pattern on Gd-BOPTA-MRI with emphasis of hepatobiliary phase.
Mamone G; Marrone G; Caruso S; Carollo V; Gentile G; Crino' F; Milazzo M; Luca A
Abdom Imaging; 2015 Oct; 40(7):2313-22. PubMed ID: 25962708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]